boditrectinib   Click here for help

GtoPdb Ligand ID: 12368

Synonyms: AUM-601 | AUM601 | CHC 2014 | CHC2014 | Chemical Compound 50 [US20160168156A1] [1] | HL 5101 | HL5101 | NOV 1601 | NOV-1601
Compound class: Synthetic organic
Comment: We mapped the structure for the INN boditrectinib via PubChem to research code AUM601, which is a selective, orally bioavailable pan-tropomyosin related kinase (TRK; a.k.a., neurotrophin tyrosine receptor kinase, NTRK) inhibitor [1]. It inhbits wild-type NTRKs and variants with resistance mutations. AUM601 is an oncology clinical lead that's being developed by AUM Biosciences. Previous research codes include CHC2014 and NOV1601.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 65.77
Molecular weight 438.2
XLogP 3.38
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(c(c1)[C@H]1CCCN1c1ccn2c(n1)c(/C=C/C(=O)N1CCNCC1)cn2)F
Isomeric SMILES C1C[C@@H](N(C1)c1nc2c(cnn2cc1)/C=C/C(=O)N1CCNCC1)c1c(ccc(c1)F)F
InChI InChI=1S/C23H24F2N6O/c24-17-4-5-19(25)18(14-17)20-2-1-10-30(20)21-7-11-31-23(28-21)16(15-27-31)3-6-22(32)29-12-8-26-9-13-29/h3-7,11,14-15,20,26H,1-2,8-10,12-13H2/b6-3+/t20-/m1/s1
InChI Key BQFYCHBYISNPFW-SQZHUTIHSA-N
No information available.
Summary of Clinical Use Click here for help
AUM601 was granted FDA orphan designation in August 2022, for the treatment of solid tumours with NTRK gene fusions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04014257 A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies Phase 1 Interventional Handok Inc.